The Master of Science degree program in Drug Discovery & Development (DDD) offers students the opportunity to understand, evaluate and engage with the entire process of drug discovery and development.
A lawyer for the U.S. Chamber of Commerce on Friday urged a federal judge to block President Joe Biden's administration from implementing a new program that would let Medicare negotiate prices with ...
The Chamber of Commerce urged a federal judge on Friday to stop the new Medicare drug price negotiation program before Oct. 1 ...
Drug companies challenging the law in court could still have several chances to stop the program before next year's election.
PhRMA, a leading drug industry trade group, and the US Chamber of Commerce have also filed suits. More on Medicare drug pricing: Medicare lists first ten drugs selected for pricing negotiations ...
One year after IRA passage, bad actors try to thwart drug price negotiation, and Biden’s efforts to defend it fall short. Merck is suing the federal government over a plan to negotiate Medicare drug ...
While only slightly past the midway point of 2023, it has already been a busy year for developments in drug pricing. Notably, CMS released its final guidance in preparation for price negotiations ...
Aug 31 (Reuters) - Drugmakers challenging a Biden administration program requiring them to negotiate with Medicare over the prices of selected costly drugs may not have a clear legal precedent on ...
The Biden administration has picked the first 10 high-priced prescription drugs subject to federal price negotiations, taking a swipe at the powerful pharmaceutical industry. It marks a major ...
A group of Republicans has called the Biden administration's list of the first 10 drugs that will face Medicare price negotiations a form of price controls that will end up leading to fewer new ...
Kathy Haan, MBA is a former financial advisor-turned-writer and business coach. For over a decade, she’s helped small business owners make money online. When she’s not trying out the latest ...
Japanese drugmaker Astellas (OTCPK:ALPMF) has withdrawn a federal lawsuit that challenged the US government’s right to negotiate drug prices for its Medicare program, but maintained the newly ...
